Ziyad Al‐Aly

163.1k total citations · 18 hit papers
109 papers, 10.6k citations indexed

About

Ziyad Al‐Aly is a scholar working on Nephrology, Infectious Diseases and Neurology. According to data from OpenAlex, Ziyad Al‐Aly has authored 109 papers receiving a total of 10.6k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Nephrology, 30 papers in Infectious Diseases and 30 papers in Neurology. Recurrent topics in Ziyad Al‐Aly's work include Long-Term Effects of COVID-19 (29 papers), COVID-19 Clinical Research Studies (27 papers) and Chronic Kidney Disease and Diabetes (20 papers). Ziyad Al‐Aly is often cited by papers focused on Long-Term Effects of COVID-19 (29 papers), COVID-19 Clinical Research Studies (27 papers) and Chronic Kidney Disease and Diabetes (20 papers). Ziyad Al‐Aly collaborates with scholars based in United States, Canada and South Africa. Ziyad Al‐Aly's co-authors include Yan Xie, Benjamin Bowe, Hong Xian, Evan Xu, Tingting Li, Yan Yan, Geetha Maddukuri, Taeyoung Choi, Sumitra Balasubramanian and Ali H. Mokdad and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Ziyad Al‐Aly

105 papers receiving 10.4k citations

Hit Papers

Long-term cardiovascular ... 2018 2026 2020 2023 2022 2021 2018 2022 2022 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Long-term cardiovascular outcomes of COVID-19
    2022 1.1k citations Yan Xie, Evan Xu et al. Nature Medicine profile →
  2. High-dimensional characterization of post-acute sequelae of COVID-19
    2021 876 citations Ziyad Al‐Aly, Yan Xie et al. profile →
  3. Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016
    2018 815 citations Yan Xie, Benjamin Bowe et al. Kidney International profile →
  4. Long COVID after breakthrough SARS-CoV-2 infection
    2022 512 citations Ziyad Al‐Aly, Benjamin Bowe et al. Nature Medicine profile →
  5. Acute and postacute sequelae associated with SARS-CoV-2 reinfection
    2022 335 citations Benjamin Bowe, Yan Xie et al. Nature Medicine profile →
  6. Long-term neurologic outcomes of COVID-19
    2022 304 citations Evan Xu, Yan Xie et al. Nature Medicine profile →
  7. Association of Treatment With Nirmatrelvir and the Risk of Post–COVID-19 Condition
    2023 184 citations Yan Xie, Taeyoung Choi et al. JAMA Internal Medicine profile →
  8. Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status
    2021 182 citations Yan Xie, Benjamin Bowe et al. profile →
  9. Postacute sequelae of COVID-19 at 2 years
    2023 170 citations Benjamin Bowe, Yan Xie et al. Nature Medicine profile →
  10. Long COVID science, research and policy
    2024 150 citations Ziyad Al‐Aly et al. Nature Medicine profile →
  11. Postacute Sequelae of SARS-CoV-2 Infection in the Pre-Delta, Delta, and Omicron Eras
    2024 99 citations Yan Xie, Taeyoung Choi et al. New England Journal of Medicine profile →
  12. Mapping the effectiveness and risks of GLP-1 receptor agonists
    2025 98 citations Yan Xie, Taeyoung Choi et al. Nature Medicine profile →
  13. Three-year outcomes of post-acute sequelae of COVID-19
    2024 93 citations Miao Cai, Yan Xie et al. Nature Medicine profile →
  14. Long-term gastrointestinal outcomes of COVID-19
    2023 79 citations Evan Xu, Yan Xie et al. profile →
  15. Long-term outcomes following hospital admission for COVID-19 versus seasonal influenza: a cohort study
    2023 73 citations Yan Xie, Taeyoung Choi et al. The Lancet Infectious Diseases profile →
  16. Risks and burdens of incident dyslipidaemia in long COVID: a cohort study
    2023 73 citations Evan Xu, Yan Xie et al. profile →
  17. Solving the puzzle of Long Covid
    2024 68 citations Ziyad Al‐Aly et al. profile →
  18. Molnupiravir and risk of post-acute sequelae of covid-19: cohort study
    2023 66 citations Yan Xie, Taeyoung Choi et al. BMJ profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ziyad Al‐Aly United States 52 3.3k 2.8k 1.8k 1.3k 1.2k 109 10.6k
Yan Xie United States 43 3.1k 0.9× 2.7k 1.0× 953 0.5× 1.2k 0.9× 1.1k 0.9× 87 9.0k
Benjamin Bowe United States 33 2.4k 0.7× 2.1k 0.8× 906 0.5× 1.2k 0.9× 892 0.7× 50 7.4k
Yu Yuan China 23 2.9k 0.9× 5.3k 1.9× 220 0.1× 598 0.5× 522 0.4× 80 9.1k
Giovanni Landoni Italy 61 1.1k 0.3× 1.3k 0.5× 1.1k 0.6× 269 0.2× 199 0.2× 525 15.1k
Carolyn S. Calfee United States 62 1.2k 0.4× 1.7k 0.6× 437 0.2× 371 0.3× 193 0.2× 218 15.5k
Todd A. MacKenzie United States 57 519 0.2× 574 0.2× 980 0.6× 217 0.2× 163 0.1× 353 11.5k
Judith S. Hochman United States 82 1.3k 0.4× 2.2k 0.8× 415 0.2× 288 0.2× 324 0.3× 360 25.8k
Morten Schmidt Denmark 44 509 0.2× 508 0.2× 343 0.2× 239 0.2× 448 0.4× 201 14.3k
Siyan Zhan China 45 1.1k 0.3× 1.9k 0.7× 195 0.1× 173 0.1× 159 0.1× 401 9.7k
Paul Welsh United Kingdom 64 357 0.1× 629 0.2× 479 0.3× 372 0.3× 325 0.3× 302 12.1k

Countries citing papers authored by Ziyad Al‐Aly

Since Specialization
Citations

This map shows the geographic impact of Ziyad Al‐Aly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ziyad Al‐Aly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ziyad Al‐Aly more than expected).

Fields of papers citing papers by Ziyad Al‐Aly

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ziyad Al‐Aly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ziyad Al‐Aly. The network helps show where Ziyad Al‐Aly may publish in the future.

Co-authorship network of co-authors of Ziyad Al‐Aly

This figure shows the co-authorship network connecting the top 25 collaborators of Ziyad Al‐Aly. A scholar is included among the top collaborators of Ziyad Al‐Aly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ziyad Al‐Aly. Ziyad Al‐Aly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cai, Miao, Evan Xu, Yan Xie, & Ziyad Al‐Aly. (2025). Rates of infection with other pathogens after a positive COVID-19 test versus a negative test in US veterans (November, 2021, to December, 2023): a retrospective cohort study. The Lancet Infectious Diseases. 25(8). 847–860. 6 indexed citations
2.
Xie, Yan, Taeyoung Choi, & Ziyad Al‐Aly. (2025). Mapping the effectiveness and risks of GLP-1 receptor agonists. Nature Medicine. 31(3). 951–962. 98 indexed citations breakdown →
3.
Xie, Yan, Taeyoung Choi, & Ziyad Al‐Aly. (2024). Postacute Sequelae of SARS-CoV-2 Infection in the Pre-Delta, Delta, and Omicron Eras. New England Journal of Medicine. 391(6). 515–525. 99 indexed citations breakdown →
4.
Xie, Yan, Taeyoung Choi, & Ziyad Al‐Aly. (2023). Risk of Death in Patients Hospitalized for COVID-19 vs Seasonal Influenza in Fall-Winter 2022-2023. JAMA. 329(19). 1697–1697. 64 indexed citations
5.
Xie, Yan, Taeyoung Choi, & Ziyad Al‐Aly. (2023). Association of Treatment With Nirmatrelvir and the Risk of Post–COVID-19 Condition. JAMA Internal Medicine. 183(6). 554–554. 184 indexed citations breakdown →
6.
Xie, Yan, Taeyoung Choi, & Ziyad Al‐Aly. (2023). Molnupiravir and risk of post-acute sequelae of covid-19: cohort study. BMJ. 381. e074572–e074572. 66 indexed citations breakdown →
7.
Xie, Yan, Benjamin Bowe, & Ziyad Al‐Aly. (2023). Nirmatrelvir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records. BMJ. 381. e073312–e073312. 29 indexed citations
8.
Al‐Aly, Ziyad. (2022). Long-term neurological sequelae of SARS-CoV-2 infection. Nature Medicine. 28(11). 2269–2270. 6 indexed citations
9.
Xie, Yan, Benjamin Bowe, Andrew K. Gibson, et al.. (2021). Clinical Implications of Estimated Glomerular Filtration Rate Dip Following Sodium‐Glucose Cotransporter‐2 Inhibitor Initiation on Cardiovascular and Kidney Outcomes. Journal of the American Heart Association. 10(11). e020237–e020237. 24 indexed citations
10.
Bowe, Benjamin, Yan Xie, Tingting Li, et al.. (2019). Estimates of the 2016 global burden of kidney disease attributable to ambient fine particulate matter air pollution. BMJ Open. 9(5). e022450–e022450. 59 indexed citations
11.
Xie, Yan, Benjamin Bowe, Ali H. Mokdad, et al.. (2018). Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney International. 94(3). 567–581. 815 indexed citations breakdown →
12.
Koraishy, Farrukh M., Benjamin Bowe, Yan Xie, Hong Xian, & Ziyad Al‐Aly. (2018). Monocyte count modifies the association between chronic kidney disease and risk of death. Clinical Nephrology. 90(3). 194–208. 5 indexed citations
13.
Xie, Yan, Benjamin Bowe, Tingting Li, et al.. (2017). Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans. BMJ Open. 7(6). e015735–e015735. 176 indexed citations
14.
Xie, Yan, Benjamin Bowe, Tingting Li, et al.. (2017). Higher blood urea nitrogen is associated with increased risk of incident diabetes mellitus. Kidney International. 93(3). 741–752. 133 indexed citations
15.
Xie, Yan, Benjamin Bowe, Tingting Li, et al.. (2016). Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD. Journal of the American Society of Nephrology. 27(10). 3153–3163. 238 indexed citations
16.
Bowe, Benjamin, Yan Xie, Hong Xian, Sumitra Balasubramanian, & Ziyad Al‐Aly. (2016). Low levels of high-density lipoprotein cholesterol increase the risk of incident kidney disease and its progression. Kidney International. 89(4). 886–896. 106 indexed citations
17.
Al‐Aly, Ziyad, Angelique Zeringue, Hong Xian, et al.. (2010). Tumor necrosis factor-α blockade, cardiovascular outcomes, and survival in rheumatoid arthritis. Translational research. 157(1). 10–18. 50 indexed citations
18.
Al‐Aly, Ziyad. (2008). The new role of calcimimetics as vasculotropic agents. Kidney International. 75(1). 9–12. 10 indexed citations
19.
Al‐Aly, Ziyad, et al.. (2007). Evaluation of serum anion gap in patients with HIV. Journal of Nephrology. 20(6). 727–730. 2 indexed citations
20.
González, Esther A., Ziyad Al‐Aly, & Kévin Martin. (2005). Difficulties in Achieving the K/DOQI Practice Guidelines for Bone and Mineral Metabolism. Seminars in Dialysis. 18(3). 171–174. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yan Xie Breakdown of academic impact, for papers by Benjamin Bowe Breakdown of academic impact, for papers by Yu Yuan Breakdown of academic impact, for papers by Giovanni Landoni Breakdown of academic impact, for papers by Carolyn S. Calfee Breakdown of academic impact, for papers by Todd A. MacKenzie Breakdown of academic impact, for papers by Judith S. Hochman Breakdown of academic impact, for papers by Morten Schmidt Breakdown of academic impact, for papers by Siyan Zhan Breakdown of academic impact, for papers by Paul Welsh
Rankless by CCL
2026